The SKBR3 cell-membrane proteome reveals telltales of aberrant cancer cell proliferation and targets for precision medicine applications

• Published in: Scientific reports 2022-06, Vol.12 (1), p.10847-20, Article 10847
• Main Authors: Karcini, Arba, Lazar, Iulia M.
• Format: Article
• Language: English
• Subjects: 631/154; 631/553; 631/57; 631/67; 692/53; Adhesion; Antigens; Apoptosis; Breast cancer; Breast Neoplasms - genetics; Cancer; CD antigens; Cell adhesion; Cell culture; Cell differentiation; Cell growth; Cell Line, Tumor; Cell Membrane - metabolism; Cell Proliferation; Cell survival; Drug development; Drug resistance; Environmental conditions; Enzymatic activity; ErbB-2 protein; Female; Gene Expression Regulation, Neoplastic; Humanities and Social Sciences; Humans; Immune response; Immunology; Immunosuppressive agents; Localization; Membrane proteins; Membranes; Mesenchyme; Metastases; Mitochondria; multidisciplinary; Nutrient transport; Precision Medicine; Protein biosynthesis; Proteins; Proteome - metabolism; Proteomics; Science; Science (multidisciplinary); Signal transduction; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-14418-0

The plasma membrane proteome resides at the interface between the extra- and intra-cellular environment and through its various roles in signal transduction, immune recognition, nutrient transport, and cell–cell/cell–matrix interactions plays an absolutely critical role in determining the fate of a cell. Our work was aimed at exploring the cell-membrane proteome of a HER2+ breast-cancer cell line (SKBR3) to identify triggers responsible for uncontrolled cell proliferation and intrinsic resources that enable detection and therapeutic interventions. To mimic environmental conditions that enable cancer cells to evolve adaptation/survival traits, cell culture was performed under serum-rich and serum-deprived conditions. Proteomic analysis enabled the identification of ~ 2000 cell-membrane proteins. Classification into proteins with receptor/enzymatic activity, CD antigens, transporters, and cell adhesion/junction proteins uncovered overlapping roles in processes that drive cell growth, apoptosis, differentiation, immune response, adhesion and migration, as well as alternate pathways for proliferation. The large number of tumor markers (> 50) and putative drug targets (> 100) exposed a vast potential for yet unexplored detection and targeting opportunities, whereas the presence of 15 antigen immunological markers enabled an assessment of epithelial, mesenchymal or stemness characteristics. Serum-starved cells displayed altered processes related to mitochondrial OXPHOS/ATP synthesis, protein folding and localization, while serum-treated cells exhibited attributes that support tissue invasion and metastasis. Altogether, our findings advance the understanding of the biological triggers that sustain aberrant cancer cell proliferation, survival and development of resistance to therapeutic drugs, and reveal vast innate opportunities for guiding immunological profiling and precision medicine applications aimed at target selection or drug discovery.